Browse list of available series in The Biomedical & Life Sciences Collection
Recommend The Biomedical & Life Sciences Collection to your librarian
Request to be kept updated on The Biomedical & Life Sciences Collection
Apply for a free trial of The Biomedical & Life Sciences Collection
View all talks & series with full access

Guest (sample access)

Optional Login with Username


        
> Home  /  Biomedical & Life ...  /  Series  /  Monoclonal Antibod...  /  Talk Details
SHARE:   Email via Outlook   Email via Web   Facebook   Twitter   |   more
Close SHARE
Please select one of the methods below to share the following page with your collegues:
Alemtuzumab (Campath-1H) in Therapy of CLL
Blogger Google Reader
Delicious Linked In
Digg MySpace
Favorites PDF Online
Gmail

Hello. As a guest, you do not have full access to this talk. Click the PLAY button below to watch the sample extract. Alternatively, you may login or review methods of obtaining more access.

    SPEAKER(S)

Prof. Kanti Rai - Long Island Jewish Medical Center, USA

Kanti R. Rai is the Joel Finkelstein Cancer Foundation Professor of Medicine at the Albert Einstein College of Medicine and Chief, Division of Hematology-Oncology, Long Island Jewish Medical Center. He is considered among leaders in the treatment of and research into chronic lymphocytic leukemia (CLL). He is an active member of the CLL-Research Consortium, an NCI-sponsored co-operative effort and the International Workshop on CLL. He is currently serving as President of the American Society of Hematology for 2006.

Talk Online Publication: Oct 2007

TOPICS COVERED IN ALEMTUZUMAB (CAMPATH-1H) IN THERAPY OF CLL

Development of Campath-1H - Burroughs-Wellcome Era (BW) - Millenium (LeukosSite)-Ilex Era (MI) - Differences between BW era and MI era - The two main trials in the BW era: study 005 in European countries and study 009 in the USA - Responses to these trials - Complications of these trials: opportunistic infection - MI era results from 1998 and study 211 (which incorporated prophylaxis against opportunistic infections) - Efficacy of Campath-1H - Examination of bone marrow biopsy specimens - Survival times - Infectious complications after first-line therapy with Campath-1H - CMV guidelines - CALGB trial

How to cite this talk:
Rai, K. (2007), "Alemtuzumab (Campath-1H) in Therapy of CLL", in Waldmann, H. (ed.), Monoclonal Antibodies as Therapeutic Agents: Fundamentals, Therapeutic Applications and Latest Advances, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/bio)

Direct talk access link:
http://hstalks.com/lib.php?t=HST47.1244&c=252

    DETAILED SLIDE INDEX

1. Introduction
2. Burroughs-welcome era (BW)
3. Millenium (LeukosSite)-ilex era (MI)
4. Campath-1H: main difference between BW and MI
5. BW era results
6. BW era results study 005
7. Infectious toxicities: Campath in 005 and 009
8. MI era results: study 211
9. Campath study 211
10. Campath-1H: most common adverse events
11. Campath for patients with B-CLL: pivotal trial
12. Efficacy of Campath in trials
13. Bone marrow biopsy specimens
14. Campath pivotal trial: overall survival
15. Infectious complications after Campath treatment
16. CMV reactivation following treatment with Campath
17. CMV guidelines
18. CALGB 19901
19. Frontline flud-(iv) Campath CALGB trial
20. Trial: Moreton et al., JCO 2005
21. Trial: Moreton 2005
22. END